Tuberculosis Transformative Science Group

The Tuberculosis Transformative Science Group (TB TSG) is responsible for development, implementation, and oversight of the ACTG research agenda related to the treatment and prevention of tuberculosis with and without HIV co-infection. The primary objectives of the TB TSG are the evaluation of anti-TB new drugs and drug combinations; development of shorter treatment regimens; treatment of MDR/XDR tuberculosis; and optimal treatment of latent tuberculosis, including MDR/XDR tuberculosis infection. Additional aims include: optimizing treatment of tuberculosis for patients receiving combination antiretroviral therapy (ART); evaluation of drug-drug interactions involving anti-TB therapy and ART; improved TB diagnostics assays and biomarkers to predict and detect disease and to monitor response to therapy; and developing novel clinical trial designs.